Japan's emerging role in the global pharmaceutical intellectual property regime: A tale of two trade agreements

Belinda Townsend, Deborah Gleeson, Ruth Lopert

    Research output: Contribution to journalArticle

    Abstract

    This paper explores Japan's role in reshaping the global pharmaceutical intellectual property regime by examining its position on the expansion of intellectual property rights (IPR) in negotiations for two regional trade agreements: the Trans Pacific Partnership Agreement (TPP) and the Regional Comprehensive Economic Partnership (RCEP). Through systematic analysis of leaked negotiating texts documenting its positions on key issues, we demonstrate Japan is now playing a pivotal role in promoting the adoption of expanded IPRs. We show that its position as IPR champion in the Asia Pacific region reflects a domestic strategy initiated in 2013 to bolster pharmaceutical export growth. Drawing on past experience and focusing on the RCEP negotiations, we explore ways in which low and middle income countries might respond to this shift in order to protect and promote access to medicines.
    Original languageEnglish
    Pages (from-to)88-103
    JournalThe Journal of World Intellectual Property
    Volume21
    Issue number1-2
    DOIs
    Publication statusPublished - 2018

    Fingerprint Dive into the research topics of 'Japan's emerging role in the global pharmaceutical intellectual property regime: A tale of two trade agreements'. Together they form a unique fingerprint.

    Cite this